KORU Medical Systems, Inc.

KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions. The company primarily serves the subcutaneous drug delivery market, adhering to the United States Food and Drug Administration (FDA) quality and regulatory system and international quality system management standards. KORU Medical focuses on its mechanical infusion products, the FREEDOM Infusion Systems, which include the FREEDOM60® Syringe Driver, the FreedomEdge® Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets™, and Precision Flow Rate Tubing™. Revenues are generated from three business sources: domestic core (US and Canada), international core, and pharma services and clinical trials. Domestic and international core revenues come from sales of syringe drivers, tubing, and needles (Product Revenue) for subcutaneous drugs cleared by the FDA for use with the FREEDOM System. The primary use is for immunoglobulin delivery to treat Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Pharma services and clinical trials revenues include Product Revenue for feasibility/clinical trials (pre-clinical studies, Phase I, Phase II, Phase III) for biopharmaceutical companies, as well as non-recurring engineering services (NRE) revenues for product innovation, testing, and registration services to customize the FREEDOM System for clinical and commercial use. The company was originally incorporated in March 1980.